Data Sheet 1_Pulmonary microbiome and metabolome signatures associate with chemotherapy response in lung cancer patients.docx

BackgroundLung cancer is a leading cause of cancer-related mortality worldwide, with chemotherapy response varying significantly among patients. Emerging evidence suggests that the pulmonary microbiota and metabolome may influence treatment outcomes, but their roles remain unclear.
MethodsThis study enrolled 25 lung cancer patients undergoing chemotherapy, categorized into chemotherapy-sensitive (n = 15) and chemotherapy-insensitive (n = 10) groups. Bronchoalveolar lavage fluid (BALF) was collected for 16S rDNA sequencing and untargeted metabolomics (LC-MS). Serum bile acids were also analyzed.
ResultsThe study identified 92 significantly altered metabolites in BALF between the two groups. Trans-urocanate showed the highest increase, while phenylalanylphenylalanine exhibited the greatest decrease in sensitive patients. Key metabolic pathways, including ABC transporters, glutathione metabolism, and bile acid biosynthesis, were enriched. Microbiome analysis revealed differential abundances of specific bacterial genera, particularly increased Caulobacter and decreased Acinetobacter in sensitive patients. Notably, serum levels of four bile acids (chenodeoxycholic acid, cholic acid, deoxycholic acid, and ursodeoxycholic acid) were significantly elevated in chemotherapy-sensitive patients, demonstrating good predictive value with AUCs ranging from 0.633 to 0.830.
ConclusionThe study highlights distinct microbial and metabolic signatures associated with chemotherapy response, suggesting potential biomarkers for personalized therapy.